Skip to content
value.today

Locus Biosciences, Inc.

🇺🇸 Raleigh, North Carolina, USABiotechnologyFounded 2015
Total raised
$19 M
3 rounds on record
Latest round
$11 M
Jan 2022
First round on record
Jan 2016
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Locus Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2022$11 MNo. 3$10 to $50 million

Locus Biosciences, Inc.: Raise no. 3, Jan 2022

Investors in this round

3 investors had bought by the notice of Feb 14, 2022: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $20 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Ousterout · Executive Officer
  • Joseph Nixon · Executive Officer
  • Paul Garofolo · Executive Officer, Director
  • Bary Bailey · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “None other than payments of salary in the ordinary course of business to certain of the parties named in response to Item 3.”

Signed by Joseph Nixon, Authorized Officer. Source: SEC Form D, newest notice filed Feb 14, 2022. Read the notice at the SEC.

equitySEC
Jul 2018$7 MIssued in a merger or acquisition$2 to $10 million

Locus Biosciences, Inc.: Private sale, Jul 2018

Investors in this round

24 investors had bought by the notice of Jul 20, 2018: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Garofolo · Executive Officer, Director
  • Bary Bailey · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The offering of shares was in consideration of substantially all of the assets of EpiBiome and, as such, the value of the Shares is indeterminate. The dollar amount set forth above represents the value ascribed by EpiBiome to the Shares.”
  • On a merger: “"The Issuer agreed to issue up to 755,747 shares of its Series A-1 Preferred Stock (the ""Shares"") for the purchase of substantially all of the assets of EpiBiome, Inc. (""EpiBiome""), subject to certain holdback and earnout provisions."”

Signed by Rebecca A. Brophy, Attorney-in-Fact. Source: SEC Form D, newest notice filed Jul 20, 2018. Read the notice at the SEC.

equitySEC
Sep 2017$7 MNo. 2$2 to $10 million

Locus Biosciences, Inc.: Raise no. 2, Sep 2017

Investors in this round

2 investors had bought by the notice of Oct 2, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $14 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Garofolo · Executive Officer, Director
  • Bary Bailey · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “EXCLUDING SALARIES PAID IN THE ORDINARY COURSE OF BUSINESS.”

Signed by Byron B. Kirkland, Attorney-in-Fact. Source: SEC Form D, newest notice filed Oct 2, 2017. Read the notice at the SEC.

equitySEC
Jan 2016$1 MNo. 1Under $2 million

Locus Biosciences, Inc.: Raise no. 1, Jan 2016

Investors in this round

62 investors had bought by the notice of Apr 15, 2016: 62 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in North Carolina

People named in the notice

  • Nick Taylor · Executive Officer
  • Paul Garofolo · Executive Officer, Director
  • Bary Bailey · Director
  • Chuck Bramlage · Director
  • David Johnston · Director
  • Geoffrey Glass · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “EXCLUDING SALARIES PAID IN THE ORDINARY COURSE OF BUSINESS.”

Signed by Byron B. Kirkland, Attorney-in-fact. Source: SEC Form D, newest notice filed Apr 15, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Locus Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2022).

    SEC Form D · Feb 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2022

That is all the official record says: Locus Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Locus Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 62 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Locus Biosciences, Inc.
NameRoleNamed in
David OusteroutExecutive officerFeb 2022
Joseph NixonExecutive officerFeb 2022
Paul GarofoloExecutive officerFeb 2022
Nick TaylorExecutive officerApr 2016
Bary BaileyDirectorFeb 2022
Paul GarofoloDirectorFeb 2022
Stuart PetersonDirectorFeb 2022
Chuck BramlageDirectorApr 2016
David JohnstonDirectorApr 2016
Geoffrey GlassDirectorApr 2016